Other than information about InVivo's first monkey trial, where can I find the data (i.e., scientific publications) from the 2nd or 3rd monkey studies that would support the company's (and your) assertion that the success in primates has been replicated?
InVivo’s first monkey trial (i.e., the study that won the prestigious APPLE award from the American Spinal Cord Association in 2011) involved a total of 4 African green monkeys with one serving as experimental control, another one receiving a scaffold-only implant, and the remaining two animals receiving the scaffold with stem cells. It’s a great science project but obviously very limited in its scope.
As an investor in this company, I want to be able to independently substantiate the repeated comments made by the CEO Mr. Reynolds suggesting that all of their monkeys “where up and running in about 3 weeks.” As such, I have been waiting for a long time to see what InVivo’s follow-up monkey studies with larger sample sizes actually would be able to demonstrate. Last November at the Piper Jaffray’s Healthcare Conference Mr. Reynolds stated that these studies employed improved assessment methods (including wireless EMG systems) and that the results were “fantastic.” He also stated during the call that “We are just about to publish that second study.” Well, unfortunately, that was over 6 months ago and he has been selling stock in the order of 1.9 million dollars since that time.
FYI, for some time now, I have closely followed the published work coming out of V. Reggie Edgerton’s lab at UCLA since Mr Reynolds often alludes to him and Dr. Edgerton serves on InVivo’s scientific advisory board. According to a quick glance at Pubmed just now (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Edgerton%20VR%22[Author]), since November 2011 Dr. Edgerton’s lab has published 12 refereed papers. Of these, two publications address a nonhuman primate model of SCI with one of them being a review article and the other an original study that involved 24 rhesus macaques that underwent C7 spinal cord at the California National Primate Research Center at UC Davis. Here are the citations:
Nout YS, Rosenzweig ES, Brock JH, Strand SC, Moseanko R, Hawbecker S, Zdunowski S, Nielson JL, Roy RR, Courtine G, Ferguson AR, Edgerton VR, Beattie MS, Bresnahan JC, Tuszynski MH. Animal models of neurologic disorders: a nonhuman primate model of spinal cord injury. Neurotherapeutics. 2012 Apr;9(2):380-92. Nout YS, Ferguson AR, Strand SC, Moseanko R, Hawbecker S, Zdunowski S, Nielson JL, Roy RR, Zhong H, Rosenzweig ES, Brock JH, Courtine G, Edgerton VR, Tuszynski MH, Beattie MS, Bresnahan JC. Methods for Functional Assessment After C7 Spinal Cord Hemisection in the Rhesus Monkey. Neurorehabil Neural Repair. 2012 Feb 13. [Epub ahead of print]
I have been unable to connect any of this research work out of Edgerton’s lab to InVivo. Interestingly, though, the authors of the recent Neurorehabil Neural Repair paper state that their study design included an examination of the efficacy of non-specified “experimental therapeutics.” However, they do not report any results in their current publication but simply state that this aspect of their work is still the subject of a continuing study.
If you can direct me to a source that allows me to independently review the definite results of InVivo's more recent monkey studies, I would appreciate it. Crede sed proba is not a bad piece of investment advice, especially for penny stocks.
Market Data 
Markets 
AI
